ERBB2 and breast carcinoma: Finally, significant differences in OS (p = 0.0147) and DFS (p = 0.0279) rates were found between animals with HER2-overexpressing mammary carcinoma showing positive CXCL12 status and cats exhibiting negative CXCL12 expression (Fig. 3a, b).